Eli Lilly Stock Falls on Slower Sales Growth of Anti-Obesity Drug
Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for diabetes drug Mounjaro and $1.
Eli Lilly (NYSE:LLY) shares sold off on Tuesday after the Indiana-based pharma giant's Q4 and 2024 preliminary sales results ...
Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...
Eli Lilly CEO confirms oral obesity drug Phase 3 results expected in Q2 Eli Lillys CEO updates on drug trials amid mixed ...
Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...
GlobalData on MSN1d
JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400mEli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.
As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
CEO Dave Ricks said Monday that the company's weight-loss pill orforglipron could receive FDA approval as soon as early 2026. Read more here.
Obesity continues to grab attention at the JP Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback